Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3

• Published in: Journal of gynecologic oncology Vol. 34; no. 2; pp. e51 - 26
• Main Authors: Lee, Jung-Yun, Lee, Yoo-Young, Park, Jeong-Yeol, Shim, Seung-Hyuk, Kim, Se Ik, Kong, Tae-Wook, Lim, Chul Kwon, Cho, Hyun Woong, Suh, Dong Hoon
• Format: Journal Article
• Language: English
• Published: Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 01.03.2023; 대한부인종양학회
• Subjects: Antineoplastic Agents - therapeutic use; Female; Genital Neoplasms, Female - drug therapy; Humans; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Poly(ADP-ribose) Polymerase Inhibitors - adverse effects; Review; Uterine Cervical Neoplasms - drug therapy; 산부인과학; Hyperthermic Intraperitoneal Chemotherapy; Molecular Targeted Therapy; Immunotherapy; Overall Survival; Poly(ADP-Ribose) Polymerase Inhibitor
• ISSN: 2005-0380; 2005-0399; 2005-0399
• DOI: 10.3802/jgo.2023.34.e51

In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitor of nuclear export. A special note was made on the withdrawal of PARP inhibitor from the market for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4 and SOLO-3 due to concerns of increased risk of death.